

# Global TB Drug Pipeline

Discovery<sup>1</sup>

Preclinical Development

Clinical Development

Lead Optimization

Preclinical Development

GLP  
Tox.

Phase I

Phase II

Phase III

Diarylquinolines

CPZEN-45

BTZ043

AZD5847

Delamanid (OPC-67683)

InhA Inhibitors

DC-159a

TBA-354

Bedaquiline (TMC-207)

Gatifloxacin

LeuRS Inhibitors

Q201

Linezolid

Moxifloxacin

Mycobacterial Gyrase  
Inhibitors

SPR-10199

Novel Regimens<sup>2</sup>

Rifapentine

Pyrazinamide Analogs

SQ609

PA-824

Riminophenazines

SQ641

Rifapentine

Ruthenium (II) complexes

SQ-109

Sutezolid (PNU-100480)

Spectinamides

Translocase-1 Inhibitors

Chemical classes: fluoroquinolone, rifamycin, oxazolidinone, nitroimidazole, diarylquinoline, benzothiazinone

<sup>1</sup> Ongoing projects without a lead compound series can be viewed at <http://www.newtbdrugs.org/pipeline-discovery.php>.

<sup>2</sup> Combination regimens: first clinical trial (NC001) of a novel TB drug regimen testing the three drug combination of PA-824, moxifloxacin, and pyrazinamide was initiated November 2010 and completed in 2011 with promising results. The second clinical trial (NC002) of this regimen was launched in March 2012 and will test the efficacy of the regimen in drug-sensitive and multidrug-resistant patients. The third clinical trial (NC003) will evaluate PA-824, TMC-207, pyrazinamide and clofazimine in combinations and is scheduled to begin September 2012.



[www.newtbdrugs.org](http://www.newtbdrugs.org)

Updated: November 13, 2012